Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
»Knuste forventningerne - spår lavere vækst,« skriver Finansavisen om Novos nye tal. Her bider man mærke i, at Novos udsigter ...
Den danske medicinalgigant Novo Nordisk overgår analytikernes forventninger med flere milliarder på en række nøgletal. Det fremgår af sundhedsgigantens årsregnskab for 2024, der er blevet ...
Lægemiddelstyrelsen i USA, FDA, har tirsdag godkendt Novo Nordisks diabetesmiddel Ozempic til behandling af kronisk ...
Det er USA's føderale fødevare- og lægemiddelmyndighed (FDA), der har godkendt medicinen, som er blevet udviklet og bliver solgt af Novo Nordisk. Dermed kan lægemidlet bruges til at behandle endnu ...
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...
Novo Nordisk shares rose sharply Friday after the ... behind blockbuster obesity treatment Wegovy and diabetes drug Ozempic is busy developing the next generation of drugs that it hopes will ...
Wegovy is Novo Nordisk's flagship obesity drug while Ozempic is its diabetes treatment. The trial was conducted on 125 overweight or obese patients and the most common side effects were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback